Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers. This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant
Introduction

Major improvements in the treatment of cancer patients have been accomplished in the few last years. The development of more effective diagnostic and prognostic methods is leading to an earlier therapeutic intervention in the clinics
. In general, the patients diagnosed with localized cancers that are treated with these conventional clinical therapies have a high response rate and a good outcome. Although these conventional therapies are effective in initial phase of treatment, the cancer progression to locally invasive and metastatic states is often associated with resistance to treatments and disease relapse, which leads to the death of the patients [1-3, 5-7, 9, 12, 13, 15-17, 21-23, 25-31] . The cancer recurrence phenomenon has been associated with the accumulating genetic and/or epigenic alterations in cancer cells that may contribute to their uncontrolled growth, survival and invasion as well as their intrinsic or acquired resistance to clinical treatments [1-3, 13, 16, 26-28, 31-41] .
The altered activation and/or overexpression of numerous growth factors, adenosine 5Ј-triphosphate (ATP)-binding cassette (ABC) multidrug efflux transporters, anti-apoptotic factors (MYC, Bcl-2, NF-B and survivin) as well as a decreased expression or activity of tumour suppressor genes (p53 and phosphatase and tensin homolog, PTEN) in cancer cells may contribute to the drug resistance and disease
relapse [1, 16, [26] [27] [28] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . [16, 35, 39, 40, [47] [48] [49] [50] [51] [52] [53] [13, 16, 30, 31, 35-37, 39-42, 46, 54-61] . Fig. 1 and 2 ) [3, 13, 37, 39-41, 47-53, 55, 57, 60, 62-65] . [39, 40, 49, 64, 72, 73, 77- [47, 59, 65-69, 72, 73, 75, 76, 82-84] [47, 66-69, 71-73, 75, 76, 82-87, 90-92] [66-69, 71-73, 75, 76, 82-84, 86] . The fact that the engrafted leukaemic or tumourigenic cells could be serially transplanted into other mice has also provided further experimental evidence of the self-renewal capacity of these cancer-initiating cells [67] [68] [69] 73, 76] . Particularly, a small number of these poorly differentiated cancer progenitor cells showed a higher leukaemic or tumourigenic potential in animal models in vivo as compared to their further differentiated progenies [67-69, 72, 75, 76, 83, 84, 86, 87] . For instance, a [54, 74-76, 80, 86-89, 94, 96-98, 101, 103] [96, 97] . [54, 97, 102, 105] . [69, 90, [106] [107] [108] [109] [110] [111] [112] [113] . In this matter, the familial genetic alterations, such as germinal mutations may notably promote the incidence of certain cancers derived from the embryonic or adult stem cells [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [118, 119] . Intriguingly, it has also been suggested that the transformed cells possessing the biomarkers and differentiating properties like embryonic hemangioblasts, which represent the putative common embryonic precursor to both haematopoietic and endothelial cell lineages (Fig. 1) , may contribute to the development of certain malignancies in adult life [123, 124] (Fig. 1) [123] . In addition, the primitive neuroectodermal tumours (PNETs) including neuroblastoma, pheochromocytoma, ependymoblastoma and pineoblastoma may also originate during the embryonic development from neuroectodermal stem cells such as neural crest stem cells ( Fig. 1) [10, 11, 121, 122, 126, 127] [128] [129] [130] [131] [132] [133] [134] [131, [133] [134] [135] [137] [138] [139] . More specifically, the multipotent BM-derived EPCs possessing the stem celllike properties may migrate into peripheral circulation and reach the tumoural sites where they can contribute to the tumour neovascularization process (Fig. 1) [39, 40, 42, 64, 69, 72, 73, 77-81, 111, 157, 158] (Fig. 1) [21, 22, 69, 90, 94, 95, 108, 109, 112, 154, 159, 160] (Fig. 1) [106, 112, 113] [108, 109] . (Fig. 1) [176] [114, 115] . More specifically, the osteoblastic sarcoma, which is the most common type of primary bone cancer, may result in distant metastases to lungs [114, 115] . The germinal mutations in retinoblastoma (Rb) and p53 tumour suppressor genes may notably promote the incidence of osteoblastic sarcoma [114] [115] [116] [117] [178] . [178] . Additionally, Ewing's sarcoma, which is a member of Ewing's family tumours (EFTs), and the second most common solid bone and soft tissue malignancy of childhood and young adults, also appears to originate from MSCs [179] . [179] . (Fig. 1) [10, 11, 29, 126, 127] (Fig. 1) [7, 15] 41, 52, 66, 67, 72, 73, 82, [180] [181] [182] . BTSCs could possess a self-renewal capacity but showed an abnormal ability to differentiate (Fig. 1) (Fig. 1) [37, 127, 157, 158] 
Recently, new concepts have been proposed on the critical implication of highly leukaemic or tumourigenic cancer progenitor cells also designated as cancer stem cells or cancer-initiating cells, in cancer initiation and progression to metastatic disease states and resistance to conventional therapies
. These cancer progenitor cell-based concepts may partially explain the recurrence of the most aggressive cancers to current clinical treatments. More specifically, the reactivation of diverse developmental signalling cascades (epidermal growth factor (EGF)/EGFR, stem cell factor (SCF)/KIT, platelet-derived growth factor (PDGF)/PDGFR, sonic hedgehog (SHH/PTCH/GLI transcription factor) and/or Wnt/␤-catenin) combined with the increased DNA repair mechanisms and ABC transporter-mediated multi-drug efflux in cancer progenitor cells may be responsible, at least in part, for their resistance to current clinical therapies
Moreover, the changes in the local microenvironment of cancer progenitor cells may also influence their behaviour. In this review, we discuss the importance of considering new concepts on the implication of cancer progenitor cells in cancer development in order to overcoming resistance to conventional cancer therapies. The emphasis is on the oncogenic events occurring frequently in cancer progenitor cells and their local microenvironment during cancer progression and the molecular mechanisms involved in their resistance to current chemotherapeutic drugs. Furthermore, we also discuss the beneficial effects of targeting different intracellular signal transduction pathways in cancer progenitor cells and their microenvironment for the development of more effective therapeutic treatments against the most aggressive and recurrent cancers.
Functions of cancer progenitor cells in the cancer initiation and progression
New model of carcinogenesis based on the cancer progenitor cells
Numerous investigations have provided evidence that the genetic and/or epigenic alterations occurring
Fig. 1 Scheme showing the critical functions assumed by cancer progenitor cells and the bone-marrow derived circulating cells in the development of leukaemias, sarcomas, brain tumours and various epithelial cancers. The accumulating genetic alterations in haematopoietic stem cells (HSCs) and/or lymphoid or myeloid precursors, which may lead to the development of leukaemias, are shown. Moreover, the genetic alteration in the embryonic hemangioblast or neuroectodermal stem cell-derived progeny, which may lead to their persistence in adult life and subsequent hemangioblastoma or neuroectodermal tumour formation, is also indicated. The genetic or epigenic alterations in neural stem cells (NSCs) and/or neuronal and glial cell lineage precursors, whose molecular events may result in their malignant transformation into brain tumour stem cells (BTSCs) and the generation of malignant neuronal and glial cell lineage precursors, are also shown. In addition, the implication of tissue-specific adult stem cells and reactive stromal host cells including the activated fibroblasts, immune cells and bone-marrow-derived endothelial progenitor cells (EPCs) in the tumour neovascularization is also illus-
. For instance, the FACS sorted SP fraction from the C6 glioma cell line may differentiate in vitro and in vivo into neurons and glia expressing the neuronal (low molecular weight neurofilament [NF-L] or ␤III-tubulin) and glial (glial fibrillary acidic protein, [GFAP]) markers, respectively, and form the metastatic tumours when injected intraperitonally in nude mice in vivo
Importantly, it has been noted that the number of cancer cells detected in the SP population versus the non-SP fraction may be significantly influenced by the experimental conditions including the source of the patients' malignant tissues (untreated, treated and/or relapsed patients) and the culture conditions used (cell density and growth factors)
In light of these observations, it appears that several types of malignant tissues and well-established cancer cell lines contain a very small population of undifferentiated or poorly differentiated cancer progenitor cells that may be responsible for the generation of leukaemia or tumour formation in animal mod
. For instance, it has been reported that the immature and tumourigenic human neuroblastoma stem cells termed as intermediate type (I-type) cells isolated from neuroblastoma tissues or cell lines were able to give rise to the neuronal cells, melanocytes and Schwann cell precursors that constitute the tumours
Influence of local tumour microenvironment on the behaviour of cancer progenitor cells
The functional properties of cancer progenitor cells may be influenced through external signals mediated by other further differentiated cancer cells and host stromal cells including activated fibroblasts and infiltrating immune cells, such as macrophages and endothelial cells
On the other hand, it has also been observed that the BCR-ABL transduction in mouse committed myeloid progenitors does not induce their malignant transformation in vitro whereas MOZ-TIF2 or MLL-ENL fusion proteins were transforming for both mouse HSCs and their more committed myeloid progenitors [107, 108, 110]. BCR-ABL-transduced mouse committed myeloid progenitors also did not generate an AML in animal model in vivo while MOZ-TIF2 or MLL-ENL-transduced-mouse myeloid progenitors were able to give rise to an AML in irradiated mouse in vivo after serial transplantations [107, 108, 110]. This suggests then that only certain types of genetic alterations may contribute to the malignant transformation of HSCs and/or the more committed haematopoietic cells during leukaemia initiation and progression. Despite the initial implication of the primitive HSCs and/or their early progeny (pre-LSCs) in the occurrence of the most the leukaemias, these observations suggest that the loss of the multi-potent or bipotent differentiating potential of LSCs may occur at an early or later stage of the disease depending on the oncogenic events occurring in the malignant
. Since MSCs are the bone-forming osteogenic progenitor cells, they may then represent the putative BM adult stem cells that may be at the origin of osteoblastic sarcoma initiation. In regard with this, it has been reported that a small population of bone sarcoma cells that are able to form the sarcospheres in culture expressed several markers of MSCs (Stro-1, CD105 and CD4) as well as the pluripotent embryonic cells (Oct-3/4 and Nanog) [177]. This supports the potential implication of MSCs in bone sarcoma development. More recently, it has been observed that the cultured murine MSC co-infused with BM into irradiated allogeneic host could drive the development of foci of sarcoma in the lungs and extremities in certain mice in vivo
The infusion of MSC-derived sarcoma cells having a cytogenetic profile comparable to human sarcoma also resulted in the malignant lesions in secondary recipients
The EFTs are generally associated with the occurrence of a chromosomal translocation that involves the fusion of a 5' segment of the EWS gene with a 3' segment of the ETS transcription factor family gene FLI-1, given the EWS-FLI-1 fusion protein. EWS-FLI-1 oncoprotein acts as an aberrant transcriptional activator and contributes to tumour development. In support with this, it has been shown that EWS-FLI-1 can transform the primary BM MSCs and generate tumours in animal models in vivo showing the phenotypic characteristics that resemble Ewing's sarcoma
Implication of cancer progenitor cells in paediatric and adult brain tumours
Primary malignant CNS tumours are the most frequent forms of solid malignant tumours diagnosed in children and the glioblastoma multiformes (GBMs) represent one of the more frequent aggressive tumour types in adults [7, 11, 15, 29]. The cellular origin of paediatric and adult brain tumour types has not yet been precisely established. The paediatric brain tumours constitute a diverse group in terms of their localization, prognosis and response to various therapeutic treatments relative to adult brain tumours
. Gliomas, which are the most common malignant primary brain tumours, include astrocytomas (grade I slow-growing pilocytic astrocytomas, grade II astrocytomas, grade III anaplastic astrocytomas and grade IV GBMs), oligodendrogliomas, ependymomas and mixed gliomas, which may contain the astrocytes, oligodendrocytes and/or ependymal cell-like cells in different proportions
. Several recent lines of evidence support the concept that certain brain cancers including medulloblastomas, astrocytomas, GBMs, oligodendrogliomas and ependymomas could derive from the malignant transformation of neural stem cells (NSCs) or more restricted-neuronal and glial cell lineage precursors into brain cancer progenitor cells also designated as brain tumour stem cells (BTSCs) [15,
. Aberrant activation of SHH pathway (SHH/PTCH/GLI), which is recognized to triggering normal growth of the cerebellum in the foetus, induced through the mutations in patched receptor (PTCH), smoothened (SMO) or
Sfu, may notably contribute to uncontrolled growth of GCPs in childhood and young children, and thereby induce the medulloblastoma formation [37, 41, 62, 111, 127, 157, 158, 183] [66, 67, 82] [72, 73] [186] [39, 40, 47, 49, 50, 54, 59, 61, 65, 68, 70, 71, 75, 76, 80, 83-87, 96, 98-105, 189] (Fig. 1, 2) [13, 31, 35-37, 39, 40, 42, 49, 54-57, 59-62, 64, 102, 190, 191] [39, 42, 47, 56, 60, 68, 75, 77, 190, [192] [193] [194] [195] [196] . It [197-200, 202, 203] . [202, 203, 207] . [1, 12, 13, 15-17, 30, 31, 35-42, 55-57, 59-62, 163, 164, 190, 191, 214, 215] [1, 12, 13, 16, 17, 26, 30, 31, 35-45, 49, 55-59, 61, 62, 64, 78, 102, 164, 190, 191, 214, 216, 217] . [12, 13, 16, 17, 24, 26, 30, 36, 37, 39, 40, 57, 216, [218] [219] [220] [13, 16, 26, 30, 35, 37, 39-41, 48, 55, 57, 59, 150, 215, 221] . Fig. 2; Table 3 ) [57, 89, 102, 191, 215, [238] [239] [240] (Table 3) [30, 131, 132, 134-136, 140, 187, 241] . Particularly (Fig. 1) [134, 136, 137, 140] 
. Similarly, the multi-potent neurosphere-like clusters isolated from adult primary GBMs can also give rise to further differentiated progenitors expressing the specific markers to three neural cell lineages including neurons (␤-III tubulin), astrocytes (GFAP) and/or oligodendrocytes (myelin or galactocerebroside) ex vitro and in vivo resembling to the cellular heterogeneity characterizing the initial GBMs
. An immunohistochemical analysis of brain tissue specimens from astrocytomas of different grades has also revealed that the number of tumour cells expressing a NSC-like phenotype (doublecortin, ␤-III-tubulin, collapsing response-mediated protein-4 [CRMP-4/TUC-4] and nestin) and proliferation marker (Ki67 antigen), was increased in high-grade astrocytomas including GBMs relative to low-grade neoplasms
Implication of cancer progenitor cells in other cancer types
